Aflac Incorporated

(New York Stock Exchange)
Back to all articles
Bullish +55

Aflac (AFL) Q2 2026 Earnings Call Transcript - The Globe and Mail

AI-generated analysis

πŸ“ˆ Net earnings per diluted share surged 46.8% to $1.63, with currency-neutral adjusted EPS reaching $1.80.

πŸ’° Total revenues declined 1% year-over-year to $4.1 billion due to a 9.3% weaker yen-dollar exchange rate.

πŸ‡―πŸ‡΅ Aflac Japan sales dropped 5.6% to JPY 19.6 billion following the launch of Miraito cancer insurance, which increased lapse activity on newer products.

πŸ“‰ Japan's benefit ratio fell 250 basis points year-over-year to 64%, though management expects full-year results at the high end of the 60%-63% guidance range.

πŸ‡ΊπŸ‡Έ Aflac U.S. sales grew 2.6% to $349 million, driven by strong performance in group voluntary benefits and network dental/vision products.

πŸ“ˆ U.S. net earned premium increased 2.3% to $1.5 billion with persistency rising to 79.4%.

πŸ’Έ Capital return of $1.3 billion included $983 million in share repurchases and $309 million in dividends paid during the quarter.

πŸ”„ Asset repositioning program moved $4.8 billion via switch trades, expected to boost annualized net investment income by $50 million.

🏦 Unencumbered liquidity stood at $3.3 billion, significantly above the $1 billion minimum balance requirement.

πŸ“Š Japan's pretax margin expanded 230 basis points to 34.3%, while U.S. pretax margin decreased 160 basis points to 20.9% due to higher disability claims.

🀝 Company expanded internal reinsurance limit relative to reserves to 30% of FSA reserves to improve balance sheet efficiency and ROE.

πŸš€ Strategic expansion includes Tsumitasu savings-type product targeting younger demographics to facilitate cross-selling of third-sector cancer and medical insurance.

Bullish Signals
  • Net earnings per diluted share increased 46.8% year-over-year to $1.63, reflecting strong operational execution.
  • Currency-neutral adjusted EPS grew 1.1% to $1.80, demonstrating underlying business strength despite currency headwinds.
  • Aflac Japan pretax margin improved 230 basis points to 34.3%, driven by favorable benefits and claims performance.
  • U.S. sales increased 2.6% year-over-year to $349 million, with group voluntary benefits exceeding internal expectations.
  • U.S. net earned premium grew 2.3% to $1.5 billion, supported by improved sales and continued premium persistency.
  • Asset repositioning program is expected to increase annualized net investment income by $50 million on a run-rate basis.
  • Company maintained its 43-year record of consecutive dividend increases while deploying capital for share repurchases.
  • Unencumbered liquidity of $3.3 billion provides significant flexibility above the $1 billion minimum balance requirement.
  • Japan's expense ratio decreased 40 basis points year-over-year to 20.2%, demonstrating effective cost management despite inflationary pressures.
  • U.S. dental and vision sales surged 47% in the second quarter, heavily driven by the agency force.
Risk Factors
  • Total revenues declined 1% year-over-year to $4.1 billion due to a 9.3% weaker yen-dollar exchange rate.
  • Aflac Japan sales decreased 5.6% in the quarter following the launch of Miraito cancer insurance, which caused elevated lapse and reissue activity on newer products.
  • Japan's benefit ratio dropped 250 basis points year-over-year to 64%, though management expects full-year results at the high end of guidance.
  • U.S. pretax margin decreased 160 basis points to 20.9% due to an increase in incurred group disability claims.
  • Corporate and Other segment reported a $10 million pretax adjusted loss, down from a $20 million gain last year, due to lower short-term income and reduced hedge benefits.
  • Aflac Japan sales for the first half of 2026 were up only 7% compared to a high prior-year baseline following the Miraito launch.
  • U.S. net earned premium growth rate for 2026 is expected to fall just below the previously guided 3% to 6% range.
Full Analysis
Aflac (NYSE:AFL) reported second-quarter 2026 net earnings per diluted share of $1.63, a 46.8% increase year-over-year, driven by strong investment income and expense management. Adjusted EPS was $1.75, with currency-neutral adjusted EPS reaching $1.80. Total revenues declined 1% to $4.1 billion compared to the prior year, primarily due to a weaker yen-dollar exchange rate impacting international operations. Aflac Japan sales decreased 5.6% to JPY 19.6 billion in the quarter following the launch of its Miraito cancer insurance product, which caused elevated lapse and reissue activity on newer products. However, the company expects full-year 2026 benefit ratios to settle at the high end of its 60% to 63% guidance range due to favorable claims performance. The Japanese segment's pretax margin improved to 34.3%, up 230 basis points year-over-year. In the United States, sales increased 2.6% to $349 million, driven by momentum in group voluntary benefits and network dental and vision products. Net earned premium rose 2.3% to $1.5 billion with persistency improving to 79.4%. Despite a rise in incurred group disability claims pushing the benefit ratio up to 49.5%, the U.S. pretax margin remained solid at 20.9%. The company executed an asset repositioning program, moving $4.8 billion of its portfolio through switch trades to capture higher yields and foreign currency gains, expected to increase annualized net investment income by $50 million. Aflac maintained its record of consecutive dividend increases, returning $1.3 billion to shareholders via share repurchases and dividends in the quarter, while keeping unencumbered liquidity at $3.3 billion.